Drug Profile
Research programme: anticoagulant - PepTx
Alternative Names: PTX003; βpep peptide PTX003Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator University of Minnesota
- Developer PepTx; University of Minnesota
- Class
- Mechanism of Action Protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Blood coagulation disorders; Thrombosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Coagulation-disorders in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Thrombosis in USA
- 25 Mar 2008 Preclinical development is ongoing